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Background: Current diagnostic tests cannot identify which infected individuals are at risk for progression to tu-
berculosis (TB). Our aim was to identify biomarkers which can predict the development of TB prior to clinical
diagnosis.
Method: In a retrospective case–control study, RNA of 14 HIV-infected drug users obtained before TB diagnosis
(cases) and of 15 who did not develop TB (controls) was analyzed for the expression of 141 genes by dcRT-
MLPA followed by Lasso regression analysis.
Findings: A combined analysis of IL13 and AIRE had the highest discriminatory power to identify cases up to 8
months prior to clinical diagnosis. Cases expressing IL13 had a gene expression pattern strongly enriched for
type I IFN related signaling genes, suggesting that these genes represent processes that contribute to TB
pathogenesis.
Interpretation:We here demonstrated that biomarkers, such as IL13-AIRE, can identify individuals that progress
to TB within a high risk population, months prior to clinical diagnosis.© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).1. Introduction
TheWHO estimates that there were 8.6 million cases of tuberculosis
and 1.3 million deaths due to tuberculosis (TB) in 2012 (World Health
Organization (WHO): Global Tuberculosis Report (2013)). Infection
withMycobacterium tuberculosis (Mtb) has an unpredictable outcome.
The proportion of individualswho truly remain infected after tuberculin
skin test (TST) or interferon gamma release assay (IGRA) conversion is
unknown (Mack et al., 2009). An estimated 5–10% of infected individ-
uals will develop pulmonary TB, mostly within the ﬁrst 2 years follow-
ing infection (Comstock et al., 1974; Vynnycky and Fine, 2000). At
present it is impossible to predict who will progress to disease and
who will remain latently infected.
Biomarkers (characteristics that can be objectively measured as in-
dicators of a pathogenic process) (Biomarkers Deﬁnitions WorkingEpidemiology, Biostatistics and
rdam, The Netherlands.
ious Diseases, Leiden University
sten@lumc.nl (S.A. Joosten).
. This is an open access article underGroup, 2001) have the potential to contribute signiﬁcantly in the battle
against Mtb. The vast majority of Mtb-infected individuals remain
healthy, suggesting that immune responses in individuals that control
latent infectionwithMtb throughout their lifetimediffer from responses
in those who develop TB within the ﬁrst years following infection
(Weiner and Kaufmann, 2014; Schuetz et al., 2011). If true, correlates
of TB progression should be identiﬁable, and these could be valuable
in early identiﬁcation of individuals at risk of developing – and transmit-
ting – TB (Ottenhoff et al., 2012a). Furthermore, in low incidence coun-
tries biomarkers predictive of TB progression would be useful in
selecting high-risk individuals for preventive therapy or regular screen-
ing. Examples are individuals with known or frequent exposure, such as
contacts of infectious pulmonary TBpatients or drug users. Likewise, TB-
HIV co-infected individuals have an increased risk of progression to TB,
reactivation of latent TB infection (LTBI) and TB relatedmortality (Nunn
et al., 2005). Determination of such biomarkers could be embedded in
existing programs in the Netherlands, inwhichHIV-infected individuals
are actively screened for TB.
Several studies have identiﬁed host gene expression patterns in the
blood from patients with pulmonary TB that differ from patterns in
latently infected individuals or patients with other inﬂammatorythe CC BY license (http://creativecommons.org/licenses/by/3.0/).
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Ottenhoff et al., 2012b; Cliff et al., 2013). Individual studies have mostly
pointed towards type I interferon (IFN) signaling components as key
markers of pulmonary TB, however, analysis of combined data indicated
that besides type I IFN signaling also myeloid cell activation, general in-
ﬂammation and B cell related markers are important players during TB
(Joosten et al., 2013). To date no studies have identiﬁed biomarkers that
can predict disease development well before the onset of clinical symp-
toms, and thus before the onset of contagious disease. The aim of this
studywas to explorewhether biomarkers exist thatmay predict clinical
TB.We used peripheral bloodmononuclear cell (PBMC) samples of HIV-
infected drugusers, participating in a unique cohort, the AmsterdamCo-
hort Study (ACS), which undertook regular blood sampling and storage
over several decades, independent from TB symptoms or diagnosis and
thus allowed retrospective selection of samples prior to TB diagnosis.
2. Materials & Methods
2.1. Study Population
The Amsterdam Cohort Study (ACS) among drug users is an open
and ongoing prospective cohort study, initiated in 1985 in
Amsterdam, the Netherlands (van den Hoek et al., 1988). The ACS was
approved by the medical ethics committee of the Academic Medical
Center of Amsterdam. Regular users of hard drugs, such as heroin, co-
caine or amphetamines, at least 3 times per week, were included in
the ACS. Enrolment is voluntary and written informed consent was ob-
tained from every participant at intake visit. Participants were asked to
return for follow-up visits every 4 to 6 months at the Public Health Ser-
vice (PHS). At every cohort visit, bloodwas drawn for laboratory testing
and storage. Blood specimens have been tested for HIV-1 antibodies
using consecutive generations of commercially available screening as-
says (obtained from Abbott Laboratories, Abbott Park, Illinois, USA;
Organon International, The Netherlands, and bioMérieux, France)
and conﬁrmed by Western blot analyses (Genelabs Diagnostics,
Singapore). Most of the participating drug users were also taking part
in the methadone substitution program of the PHS Amsterdam. Metha-
done clients participating in the ACS were screened for tuberculosis at
the TB department of the PHS Amsterdam by chest radiograph at six
month intervals. A TB diagnosis was made by specialized TB clinicians,
based on symptoms, chest radiograph, sputum smear and culture re-
sults, and/or by clinical response to treatment, based on national guide-
lines (KNCVTuberculosis Foundation, 2008). In this cohort HIV infection
increased the risk of tuberculosis 13-fold (Keizer et al., 2000). Since
PBMCswere stored prospectively over decades, samples prior to clinical
diagnosis of TB were available, and could be used to study gene expres-
sion proﬁles before the onset of TB.
2.2. Sample Selection
Twenty HIV-infected drug users diagnosed with TB in the period
1985–2012 were selected as cases using the ACS cohort database. A re-
quirement was that at least one stored PBMC sample was available in
the sample repository in the 365-day period preceding the date of the
TB diagnosis. We preferred to select samples taken about 6 months be-
fore TB diagnosis, but we were limited in the number of samples avail-
able prior to TB diagnosis, as many samples from this cohort were
already used for other research purposes. All TB cases with samples col-
lected N180 days before diagnosis were invited for at least 1 ACS cohort
follow-up visit after the point of sample collection. Thirty HIV-infected
drug users who were not diagnosed with TB in the same cohort period
were selected as controls. The controls were frequency-matched for
age, gender and CD4 cell count. At time of analysis, all controls were at
least 4 years passed the PBMC collection time point and were not diag-
nosed with TB so far.We checked the clinical ﬁles of the TB department to obtain details
on TBdiagnosis. In the process it was found that one casewas diagnosed
with LTBI (and not TB) at a time point shortly after sample collection; he
developed TB 8 years later. Therefore this personwas excluded from the
analysis. Among the remaining 49 samples, from 29 (14 cases and 15
controls) sufﬁcient good quality RNA was isolated for analysis. The 29
participants with sufﬁcient RNA in their samples did not differ signif-
icantly from the other 20, in terms of age, gender, CD4 cell count,
calendar period of sample, and TB status (case or control). Among
the 29 included participants, cases did not differ signiﬁcantly from
controls in these respects (Table 1). The majority of cases were clas-
siﬁed as PTB (57%) or PTB + EPTB (29%) and diagnosis was based on
culture (86%) or clinical response to treatment (14%) (Table 1).
There were no previous episodes of TB reported for any of the partic-
ipants, cases or controls.
2.3. RNA Extraction
PBMCs were thawed using 50% FCS (Greiner Bio-One, Alphen aan
den Rijn, the Netherlands), washed in PBS and the pellet was directly
dissolved in 1 ml Trizol (Invitrogen, Thermo Fisher Scientiﬁc Inc.,
Merelbeke, Belgium). Total RNA was extracted according to standard
protocols recommended by the manufacturer. RNA was quantiﬁed
using a Nanodrop ND-1000 spectrophotometer and diluted to 50 ng/μl
for use in dcRT-MLPA.
2.4. dcRT-MLPA Assay, Data Analysis and Quality Control
A dual-color reverse transcriptase multiplex ligation-dependent
probe ampliﬁcation (dcRT-MLPA) assay was performed as de-
scribed previously (Joosten et al., 2012). Brieﬂy, for each target-
speciﬁc sequence, a speciﬁc RT primer was designed, located imme-
diately downstream of the left and right hand half-probe target
sequence. Following reverse transcription of 125 ng RNA using
MMLV reverse transcriptase (Promega, Leiden, the Netherlands),
left and right hand half-probes were hybridized to the cDNA at 60 °C
overnight. Annealed half-probes were ligated and subsequently ampli-
ﬁed by PCR (33 cycles of 30 s at 95 °C, 30 s at 58 °C and 60 s at 72 °C,
followed by 1 cycle of 20 min at 72 °C). Primers and probes were from
Sigma-Aldrich Chemie (Zwijndrecht, the Netherlands) (Joosten
et al., 2012; Geluk et al., 2014) and MLPA reagents from MRC-
Holland (Amsterdam, the Netherlands). PCR ampliﬁcation prod-
ucts were 1:10 diluted in HiDi formamide containing 400HD
ROX size standard and analyzed on an Applied Biosystems 3730
capillary sequencer in GeneScan mode (BaseClear, Leiden, the
Netherlands).
Trace data were analyzed using the GeneMapper software pack-
age (Applied Biosystems). Signals below the threshold value for
noise cut-off in GeneMapper (peak area below log2(200) = 7.64)
were assigned the threshold value for noise cut-off. Subsequently,
results from target genes were normalized to the average signal of
housekeeping gene GAPDH and assigned the threshold value if
below 7.64.
2.5. Statistical Analysis
Gene expression levels among cases and controls were plotted after
log2 normalization and differences between cases and controls were
compared using Mann–Whitney U testing; differences in expression
were considered signiﬁcant when P b 0.05. P-values for each individual
comparison were corrected for multiple testing using the Benjamini–
Hochberg adjustment (Benjamini and Hochberg, 1995). All gene ex-
pression data obtained using dcRT-MLPAwere analyzed using Lasso re-
gression analysis to identify the combined biomarkers with the highest
discriminative power between cases and controls (Tibshirani, 1996).
Lasso regression analysis is a shrinkage and selection method for linear
Table 1
Demographic and clinical characteristics of HIV-infected individuals participating in the Amsterdam Cohort Studies included in the study.
Cases
n (%)
Cases IL13
pos n (%)
Cases IL13
neg n (%)
Controls
n (%)
P-value1 P-value2 P-value3
Total 14 6 8 15
Sex
Male 12 (86) 4 (67) 8 (100) 13 (87) 1.000a 0.544a 0.165a
Female 2 (14) 2 (33) 0 (0) 2 (13)
Age
Years; median (IQR) 38 (33–41) 37 (31–40) 39 (33–44) 37 (35–46) 0.847b 0.622b 0.414b
25–34 5 (36) 2 (33) 3 (38) 3 (20) 0.632a 0.534a 0.627a
35–44 7 (50) 4 (67) 3 (38) 8 (53)
≥45 2 (14) 0 (0) 2 (25) 4 (27)
TB classiﬁcation
PTB 8 (57) 5 (83) 3 (38) 0.096a
EPTB 2 (14) 1 (17) 1 (13)
PTB + EPTB 4 (29) 0 (0) 4 (50)
Sputum smear status
Smear-positive 7 (50) 3 (50) 4 (50) 1.000a
Smear-negative 5 (36) 2 (33) 3 (38)
NA⁎ 2 (14) 1 (17) 1 (13)
Culture status
Positive 12 (86) 5 (83) 7 (88) 1.000a
Negative⁎⁎ 2 (14) 1 (17) 1 (13)
CD4 cell count
Cells per mm3; median (IQR) 270 (168–400) 315 (260–603) 190 (138–325) 340 (220–430) 0.354 b 0.622b 0.081b
Viral load⁎⁎⁎
By p24 ELISA (pg/ml); median (IQR)
(n = 17)
18 (0–101) (n = 10) 32 (14–154) (n = 5) 0 (0–56) (n = 5) 0 (0–112) (n = 7) 0.417b 0.106b 0.095b
By RNA (copies/ml); median (IQR)
(n = 12)
13,000 (2863–191,250)
(n = 4)
11,000 (n = 1)c 150, 15,000, 250,000
(n = 3)c
8300 (400–62,905)
(n = 8)
0.932b 1.000b 1.000b
Extent of lung damage on chest X-ray
Mild 4 (29) 2 (33) 2 (25) 0.571a
Moderate 6 (43) 3 (50) 3 (38)
Extensive 2 (14) 0 (0) 2 (25)
NA⁎ 2 (14) 1 (17) 1 (13)
Calendar period of sample (year)
1985–1993 5 (36) 3 (50) 2 (25) 4 (27) 0.791 a 0.311a 0.627a
1994–2002 7 (50) 3 (50) 4 (50) 7 (47)
≥2003 2 (14) 0 (0) 2 (25) 4 (27)
P-values represent:
1 Comparison between all TB cases and all controls.
2 Comparison between IL13 positive cases and all controls.
3 Comparison between IL13 positive cases and IL13 negative cases.
a Tested by Fisher's Exact Test.
b Tested by Mann–Whitney U test (using exact signiﬁcance).
c Numbers too small to calculate median and IQR.
⁎ NA= these represent the 2 TB cases with EPTB; this category was excluded from analysis comparing IL13 positive and IL13 negative cases.
⁎⁎ Both culture negative TB cases responded to treatment.
⁎⁎⁎ A p24 ELISA was done for all cases and controls sampled before 1997, and a RNA test was done for all cases and controls sampled thereafter.
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a bound on the sum of the absolute values of the coefﬁcients
(Tibshirani, 1996). Lasso has been previously used to identify biomarker
signatures with the best predictive value between TB cases and
individuals with LTBI (Joosten et al., 2012). The classifying capability
of the biomarkers signatures is displayed as a receiver operating
characteristics(ROC) curve, in which the true-positive rate (sensitivity)
is plotted against the false positive rate (1 — speciﬁcity). The relation-
ship between gene expression and time to TB diagnosis was assessed
using linear regression analysis.
Molecular interactions between statistically signiﬁcantly differently
expressed genes were integrated using ‘Ingenuity Pathway Analysis’
(IPA) (www.ingenuity.com). Results were visualized as networks and
ranked as canonical pathways. All analyses were completed in SPSS
21.0 (SPSS, Chicago, IL), GraphPad Prism (6.02, Graphpad Software
Inc., La Jolla, Ca), and statistical programR version 2.11.0 (R Foundation,
Vienna, Austria).3. Results
3.1. Cases Can Be Identiﬁed Prior to Diagnosis Based on Gene Expression
Patterns
Expression patterns of human innate and adaptive immune re-
sponse genes and genes known to be associated with TB were deter-
mined in samples from 14 cases prior to TB diagnosis and samples of
15 controls. Gene expression levels among cases and controls for a se-
lection of the 141 included genes are presented in scatter plots
(Fig. 1). Included were genes signiﬁcantly differently expressed be-
tween cases and controls, and genes associated with known cellular re-
sponses. Fig. 1A depicts genes known to play a role in Th1, Th2 and
regulatory T cell (Treg) associated immune responses. Generally these
genes were expressed at equal levels in cases and controls, however
the Th2 related gene IL13 (encoding interleukin 13) showed signiﬁcant-
ly increased expression in cases compared to controls. Signiﬁcant IL13
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Fig. 1. Differential gene expression pattern prior to TB diagnosis in cases versus controls. RNA was isolated from total PBMCs and gene expression levels were determined using dcRT-
MLPA. Gene expression levels were normalized to the housekeeping gene GAPDH and log2 transformed before plotting. Cases (closed circles) and controls (open circles) were compared
using Mann–Whitney testing and P values were shown for genes P b 0.1. A. Genes associated with Th1, Th2 and Treg function. B. Genes associated with general T-cell characteristics and
genes associated with myeloid cell function. C. Genes previously reported to be important biomarkers in patients with TB disease at time of diagnosis. D. Genes belonging to the type I
interferon signaling pathway, a pathway demonstrated to be highly active during active TB disease.
175R. Sloot et al. / EBioMedicine 2 (2015) 172–179gene expression was observed in 6/14 cases but in none of the controls.
Fig. 1B includes genes expressed during general T cell development and
genes associated with myeloid lineages. AIRE (APECED, autoimmune
regulator) showed a signiﬁcantly increased expression in controls com-
pared to cases. Moreover, expression of the chemokine CCL4 (MIP1β)
was increased in cases compared to controls (P=0.051). In Fig. 1C a se-
ries of genes previously identiﬁed as biomarkers of active TB is shown;CASP8 (encoding caspase 8) and SPP1 (Secreted Phosphoprotein
1) showed a signiﬁcant increase in cases compared to controls. Finally,
Fig. 1D contains genes associated with type I IFN signaling, of which
many have been previously identiﬁed as markers of active TB (Berry
et al., 2010; Maertzdorf et al., 2011a,b, 2012; Ottenhoff et al., 2012b;
Cliff et al., 2013). None of these genes were expressed signiﬁcantly dif-
ferently between cases and controls. P values for the comparison of
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Fig. 3. Gene expression and time to diagnosis. GAPDH normalized and log2 transformed
gene expression levels of IL13were plotted against time to TB diagnosis (in days): samples
above the threshold of 7.64 represent cases expressing IL13 (IL13+). The relationship be-
tween gene expression of IL13 and time to TB diagnosis was analyzed using linear regres-
sion analysis.
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Fig. 4A. After adjusting for multiple testing, none of the genes remained
signiﬁcantly differentially expressed between cases and controls.
Lasso regression analysis was used to determine biomarker signa-
tures with the highest discriminatory power. The biomarker signature
that classiﬁed controls versus cases included 2 genes, AIRE, with in-
creased expression in controls (β,−0.04) and IL13, with increased ex-
pression in cases (β, 0.41). The classifying value of these biomarkers is
displayed as a receiver operating characteristic curve (area under the
curve (AUC) = 80.0%) (Fig. 2).
3.2. IL13 Expressing Cases Show Hallmark of Type I IFN Response
Expression of IL13 was restricted to a subgroup of cases (n = 6/14)
and the level of normalized IL13 in that subgroup correlated with time
to TB diagnosis (r = −0.938, P = 0.006) (Fig. 3). The majority (5/6)
of IL13+ caseswere sampled between 190–250 days prior to TB diagno-
sis and the remaining case close to (on day 55 before) TB diagnosis.
Since expression of IL13 was the most discriminatory factor accord-
ing to Lasso regression analysis we reanalyzed gene expression data
using only samples of cases expressing IL13 and of all controls to obtain
more insights into the pathophysiology of the disease. Focussed analysis
of IL13+ cases revealed 50 genes that were signiﬁcantly differently
expressed between the study groups (n = 6 cases, n = 15 controls)
(Fig. 4A). Interestingly, a considerable number of these genes (n =
19/50) belonged to type I IFN signaling and reached high levels of signif-
icance (n = 7/19 with P b 0.01) in the comparison of IL13+ cases with
controls (Fig. 4B). All genes signiﬁcantly differently expressed showed
increased expression in cases compared to controls. In addition, a
large proportion of genes associated with immune activation and in-
ﬂammation became signiﬁcant in the comparison of the subgroup of
cases expressing IL13with controls. Indeed, Ingenuity PathwayAnalysis
on all 50 genes that were signiﬁcantly differently expressed between
IL13+ cases and controls revealed a key role for type I IFN signaling
within the IL13+ cases, suggesting that type I IFN plays a role in TB de-
velopment in these cases (Fig. 4C). After adjusting for multiple testing
using the Benjamini–Hochberg correction 22 of the 50 genes remained
signiﬁcantly differently expressed between cases and controls (present-
ed in bold, Fig. 4A, B).
4. Discussion
Identiﬁcation of individuals at high risk of developing pulmonary TB
is not possible with the currently available biomarkers and diagnosticLasso regression:
Gene Beta
(Intercept) -3.02
AIRE -0.04
IL13 0.41
AUC = 80.0%
Fig. 2. IL13 and AIRE are biomarkers discriminating cases and controls. All gene expression
data obtained using dcRT-MLPA were analyzed using Lasso regression analysis to identify
the biomarkers that contribute to the discrimination between cases and controls. Receiver
operator characteristic (ROC) curve shows discriminative power of combined signature of
IL13 and AIRE for the prediction of TB disease development.tools. Here we have studied a unique sample set consisting of samples
of HIV-infected drug users prior to diagnosis of pulmonary TB, which
allowed identiﬁcation of biomarkers that predict TB development
months before clinical diagnosis of TB. To the best of our knowledge
this is the ﬁrst demonstration of biomarkers predictive of TB cases be-
fore clinical diagnosis. Application of such biomarkers in particular
high risk populations could potentially identify individuals that might
beneﬁt from preventive treatment before contagious disease has
developed.
The combination of IL13 and AIRE expressions appeared to classify
cases versus controls with the highest discriminatory power among
our gene sets. The majority of case samples expressing IL13 had been
obtained 190–250 days prior to TB diagnosis, suggesting that these
combined markers are able to identify individuals that will progress to
TB disease within 8 months prior to diagnosis. Screening for such
markers could allow early identiﬁcation and subsequent treatment of
individuals at high risk of developing disease, such as homeless, drug
users, recent TST converters following contact in low endemic areas or
HIV-infected individuals. Identiﬁcation before the development of con-
tagious TB would help in limiting transmission of infection, and, early
treatment of cases could reducemorbidity andminimize complications.
IL13 was expressed in about half of the cases up to 250 days prior to
diagnosis. Since it cannot be formally excluded that the other eight cases
were not yet infected with Mtb (all N140 days prior to diagnosis) and
therefore did not show speciﬁc gene expression patterns, we focussed
on the IL13 expressing cases to obtainmore insights into thepathophys-
iology of TB. Restricting analysis to the 15 controls and the IL13+ cases
identiﬁed 50 genes that were signiﬁcantly differently expressed be-
tween IL13+ cases and controls. Interestingly, many of these differen-
tially expressed genes belong to the type I IFN signature that previous
studies have consistently reported to discriminate patients with pulmo-
nary TB at the moment of diagnosis from healthy controls (Berry et al.,
2010; Maertzdorf et al., 2011a,b, 2012; Ottenhoff et al., 2012b; Cliff
et al., 2013). Identifying a similar pattern up to 8months before TB diag-
nosis strengthens our ﬁndings that it is possible to predict TB months
before diagnosis and that genes identiﬁed here play a role in the devel-
opment of TB. This was further supported by the high number of genes
that remained signiﬁcantly associated with subsequent TB disease de-
velopment after multiple testing correction, indicating that selected
genes could be strong predictors for TB development with increasing
sample sizes.
Type 1 interferon signaling has been identiﬁed not only as a bio-
marker of TB disease but also as a key player in mycobacterial disease
pathogenesis. In leprosy, IFNγ-induced antimicrobial genes were most-
ly detected in self-healing tuberculoid lesions, whereas type I interferon
AB
C
p: >0.1
p: 0.05 - 0.1
p: 0.01 - 0.05
p: 0.001 - 0.01
p: <0.001
all cases
IL13+ cases only
all cases
IL13+ cases only
AB
R
AI
RE
AR
EG
AS
AP
1
BC
L2
BL
R1
BM
P6
BP
I
CA
SP
8
CC
L1
1
CC
L1
3
CC
L1
9
CC
L2
CC
L2
2
CC
L3
CC
L4
CC
L5
CC
R7
CD
14
CD
16
3
CD
19
CD
20
9
CD
27
4
CD
3E
CD
4
CD
8A
CL
EC
7A
CT
LA
4
CX
3C
L1
CX
CL
10
CX
CL
13
CX
CL
9
DS
E
EG
F
FA
SL
G
FC
GR
1A
FL
CN
1
FO
XP
3
FP
R1
GA
TA
3
GB
P1
GB
P2
GB
P5
GN
LY
GZ
M
A
GZ
M
B
HC
K
HP
RT
all cases
IL13+ cases only
IF
I1
6
IF
I3
5
IF
I4
4
IF
I4
4L
IF
I6
IF
IH
1
IF
IT
2
IF
IT
3
IF
IT
5
IF
IT
M
3
IF
NG
IL
10
IL
12
A
IL
12
B
IL
13
IL
15
IL
17
A
IL
1B
IL
22
RA
1
IL
23
A
IL
2R
A
IL
4
IL
4d
2
IL
5
IL
6
IL
7R
IL
9
IN
DO
IR
F7
KI
F1
B
LA
G3
LT
F
LY
N
M
AR
CO
M
M
P9
M
RC
1
M
RC
2
NC
AM
1
NE
DD
4L
NL
RC
4
NL
RP
1
NL
RP
10
NL
RP
11
NL
RP
12
NL
RP
13
NL
RP
2
NL
RP
3
NL
RP
4
93
23 0.01
NL
RP
6
NL
RP
7
NO
D1
NO
D2
OA
S1
OA
S2
OA
S3
PR
F1
PT
PR
Cv
1
PT
PR
Cv
2
RA
B1
3
RA
B2
4
RA
B3
3A
RO
RC
SE
C1
4L
SL
AM
F7
SO
CS
1
SP
P1
ST
AT
1
ST
AT
2
TA
GA
P
TA
P1
TA
P2
TB
C1
D7
TB
X2
1
TG
FB
1
TG
FB
R2
TI
M
P2
TL
R1
TL
R1
0
TL
R2
TL
R3
TL
R4
TL
R5
TL
R6
TL
R7
TL
R8
TL
R9
TN
F
TN
FR
SF
18
TN
FR
SF
1A
TN
FR
SF
1B
TN
IP
1
TW
IS
T1
VE
GF
ZN
F3
31
ZN
F5
32
Fig. 4. IL13 expressing cases show signature of type I IFN signaling prior to diagnosis. dcRT-MLPA derived gene expression datawere reanalyzed using only those cases that expressed IL13
to obtain insights into the pathophysiological process ongoing in these patients-to-be. A. Mann–Whitney testing was performed comparing both the total set of cases with the controls as
well as comparing only cases expressing IL13with all controls; resulting P-valueswere color coded to visualize genes that were expressed signiﬁcantly differently. Genes in bold remained
signiﬁcantly differently expressed after multiple testing correction. B. Expression levels of type I interferon related genes are shown only for cases (ﬁlled symbols) expressing IL13 and all
controls (open circles). Mann–Whitney testingwas used to identify differentially expressed genes: *P b 0.05; **P b 0.01. Stars in bold remained signiﬁcantly different after multiple testing
correction. C. Ingenuity based pathway analysis of all genes signiﬁcantly different between controls and IL13+ cases. Genes presented in green remained signiﬁcantly differently expressed
after multiple testing correction.
177R. Sloot et al. / EBioMedicine 2 (2015) 172–179related genes were preferentially expressed in disseminated and pro-
gressive lepromatous lesions (Teles et al., 2013). Excessive type I re-
sponses have been linked to TB disease exacerbation, the balance of
which is tightly controlled by IL-1 and eicosanoids (Mayer-Barber
et al., 2014). InMtb infected mice type I interferon receptor deﬁciency
resulted in reduced pathology due to alterations in early, innateimmune responses (Dorhoi et al., 2014). Indeed, limitation of type I in-
terferons promoted bacterial containment, and immunotherapy with
drugs that augment the eicosanoid prostaglandin E2, indirectly down-
regulating type I interferons, prevented death in Mtb infected mice
(Mayer-Barber et al., 2014). These ﬁndings support the pathogenic
role of type I interferons in TB.
178 R. Sloot et al. / EBioMedicine 2 (2015) 172–179This study identiﬁed human biomarkers with a potential to prospec-
tively identify individuals that develop TB, a ﬁnding that may have sig-
niﬁcant implications for early TB diagnosis and treatment. We do
acknowledge that our study sample set is small and that our work
only provides a proof-of-concept. A larger sample set as well as longitu-
dinal studies will be required to determine optimal signatures and to
determine the relevant time window preceding TB diagnosis. Our data
indicate that a predictive signature can be detected in ex vivo blood
up to 6–8 months prior to clinical diagnosis and these ﬁndings support
continuation of the search for predictive biomarkers. Several additional
factors have to be considered in interpreting ourﬁndings. First, only fro-
zen PBMCswere available for analysis and thus RNAwas extracted from
(unstimulated) PBMCs, however we expect that ﬁxed whole blood (e.g.
PAXgene or Tempus tubes) will give similar results as previous studies
on PBMCs and whole blood RNA revealed similar patterns (Joosten
et al., 2013). If longitudinal samples from a larger, well deﬁned cohort
are available, such as the GC6 cohort (The GC#6–74 Consortium),
gene expression analyses should preferably be performed in an unbi-
ased manner, e.g. using RNA sequencing. Secondly, our cohort was re-
stricted to HIV-infected individuals, mostly males, thus future studies
should investigate whether our ﬁndings are generalizable to HIV-
negative individuals and to females. However, biomarkers in HIV-
infected individuals found in our study were similar to previously iden-
tiﬁed markers in HIV-uninfected individuals (Berry et al., 2010;
Maertzdorf et al., 2011a,b, 2012; Ottenhoff et al., 2012b; Cliff et al.,
2013), suggesting that many are common and not speciﬁc for HIV-
infected TB patients. Thirdly, unfortunately no information on socioeco-
nomic status, alcohol abuse or comorbidities (e.g. other infections, dia-
betes) on individual basis was registered for this cohort, but we
should strongly recommend to assess these parameters in future studies
as theymight be associated with the risk of progression to TB. Finally, in
our cohort timing of TB contact and thus potential time of infectionwas
not deﬁned, nor were routine tests performed to determine infection
status of cohort participants (as this was outside the scope of the ACS
when it was set up in 1985). We limited our sample set to a time win-
dow of 1 year prior to diagnosis as we assumed that most individuals
that develop TB will do so within 1–2 years following infection. Still
we cannot exclude that some cases were not yet infected at the time
of blood sampling. In particular, some cases that were diagnosed more
than 8 months after sample collection might not have been infected
yet at time of sampling.
The identiﬁcation of IL13 as a potentially predictive biomarker of
TB cases is interesting as Th2 immunity and in particular IL13 have
recently been associated with pathology in inﬂammatory disorders
including TB. In murine Mtb infection studies IL13 was associated
with tuberculosis associated pathology; overexpressing IL13 result-
ed in enhanced pathology mimicking human TB lesions (Heitmann
et al., 2014). Moreover, the expression of IL-13 and the Th2 tran-
scription factor GATA3 by human CD8+ T-cells have been associated
with several inﬂammatory disorders involving tissue ﬁbrosis includ-
ing atopic dermatitis, psoriasis and sclerosis (Medsger et al., 2011;
Hijnen et al., 2013; Fuschiotti et al., 2009, 2013). Also in human aller-
gic asthma, IL-13-producing CD8+ T-cells isolated from the lung are
increased and associated with airway obstruction (Dakhama et al.,
2013). Together these studies suggest that IL-13-producing CD8+
T-cells are important players in the development of inﬂammatory
disorders in the lung. mRNA levels for IL13 were also found to be
increased in Mtb infected human lymph nodes, indicating local IL13
expression in Mtb lesions, although the cellular source remained
undeﬁned (Rahman et al., 2009). We have also recently identiﬁed an
unusual subset of humanMtb speciﬁc CD8+ T-cells that produce IL-13
(vanMeijgaarden K.E., HaksM.C., Ottenhoff T.H.M., Joosten S.A., submit-
ted), suggesting a contribution of these cells in TB pathogenesis.
In conclusion, we show here that host biomarkers predictive of TB
disease development up to 8 months prior to TB diagnosis exist, and
can be identiﬁed directly ex vivo without antigen speciﬁc activation orenrichment steps. Analyses need to be repeated on larger, well deﬁned
cohorts with advanced state-of-the-art methods.
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